Evidence map›Paper›PMID 42291099›Full record

ArticleCytoJournal2026

A case of inappropriate thyroid-stimulating hormone secretion syndrome after thalidomide treatment.

Yanju Zhu, Juan Chen

Abstract readCase Reports
In one paragraph

Article in CytoJournal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Yanju ZhuDepartment of Clinical Laboratory, Hangzhou Xixi Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, China.
Juan ChenDepartment of Endocrinology, Hangzhou Xixi Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thalidomide is used for the management of several diseases, including the treatment of certain dermatological conditions. We report a case of thyroid dysfunction, characterized by a high serum thyroid-stimulating hormone (TSH) level accompanied by high free triiodothyronine (FT3) and free thyroxine (FT4), in a patient with preexisting hypothyroidism and human immunodeficiency virus (HIV) infection during thalidomide treatment. The case provides a novel pattern of thyroid dysfunction induced by thalidomide, differing from classical thyroid disease. We recommended a measurement of baseline thyroid function and TRAb before thalidomide treatment, every 2 weeks during the initial 1-3 months, and then monthly.

Indexed as

Human immunodeficiency virusHypothyroidismInappropriate thyroid-stimulating hormone secretion syndromeThalidomideThyroid dysfunction

Identifiers

PMID42291099
PMCPMC13255163

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.